Sparrow Pharmaceuticals key facts
as of Oct 2026- Operator of a cardiometabolic therapeutics platform intended to address treatment-resistant diabetes and related metabolic conditions.
- Sparrow Pharmaceuticals is valued at approximately $139.0M as of Oct 2026, set at its later-stage round, Sep 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $145.8M across 4 recorded rounds; the latest was Later Stage VC (Series B) ($95.0M) in Sep 2025.
- Notable investors include RA Capital Management, Keiretsu Forum, Matter (Consulting Services (B2B)), OrbiMed, Forbion — 11 tracked in total.
- Sparrow Pharmaceuticals has filed 5 Form Ds with the SEC since 2019, most recently Jul 2025 ($61.8M sold to 17 investors).
- Status: Privately Held (backing).
Valued at $139.0M at its later-stage round, Sep 2025. Nothing has traded since.
- ·The complete investor list: 11 names
- ·Watch Sparrow Pharmaceuticals: the Monday email on marks, rounds and moves
Sparrow Pharmaceuticals funding rounds
4 roundsWho backs Sparrow Pharmaceuticals
11+Sparrow Pharmaceuticals valuation
Sparrow Pharmaceuticals was valued at $139 million at its later-stage round in Sep 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Sparrow Pharmaceuticals raised?
Sparrow Pharmaceuticals has raised $146 million across 4 recorded rounds since 2018. The largest was a $95 million Series B in Sep 2025.
Sparrow Pharmaceuticals has filed 5 Form Ds with the SEC since 2019, most recently in Jul 2025 ($61.8 million sold to 17 investors).
Sparrow Pharmaceuticals investors
11 investors are on record for Sparrow Pharmaceuticals, including RA Capital Management, Keiretsu Forum, Matter (Consulting Services (B2B)) and OrbiMed. The Series B in Sep 2025 drew 4 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Alchemab Therapeutics ($138 million), Imbria Pharmaceuticals ($132 million) and Tahoe ($131 million).
About Sparrow Pharmaceuticals
Operator of a cardiometabolic therapeutics platform intended to address treatment-resistant diabetes and related metabolic conditions. The company offers a novel oral hydroxysteroid dehydrogenase type 1 inhibitor targeting disease progression mechanisms, enabling patients with type 2 diabetes and elevated cortisol to achieve improved glycemic control with fewer side effects and simplified treatment.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Portland, OR, United States
- Founded
- 2013
- Employees
- 10
- Website
- sparrowpharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.